Although some studies reported that FGFR2 was overexpressed in 31.1% of GC patients and might be associated with vascular invasion, FGFR2 amplification enhanced the sensitivity of regorafenib in gastric cancer and colorectal cancer [35, 36]. Here, FGFR2 is linked to colorectal cancer.